Eli Lilly Alzheimer's Drug Gets Ad Comm Thumbs-Up For Early-Stage Patients

By Maaisha Osman, Jessica Karins / June 10, 2024 at 7:15 PM
FDA’s advisors voted 11-0 in favor of approval of Eli Lilly’s Alzheimer’s disease drug donanemab, saying data show the treatment is likely to benefit people with early stage Alzheimer’s disease, including people with low or zero levels of tau proteins in their brain, a group that was not part pf Lilly’s trial. The panelists, who met Monday (June 10) to consider the drug application, also cautioned the benefits of donanemab outweigh the risks as long as the risks are monitored...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.